Bibliographic Details
| Title: |
Real word effectiveness of benralizumab in mexican patients with severe eosinophilic asthma: Responders and super-responders. |
| Alternate Title: |
Efectividad real de benralizumab en pacientes mexicanos con asma eosinofílica grave: respondedores y superrespondedores. |
| Authors: |
Ramírez, Ulises NoelGarcía1, Aguilar Hinojosa, Nadia Karina2, Reyes, Saraid Cerda3, Campos Gutiérrez, Rosa Isela3, Castillón Benavides, Nidia Karen4, Velasco Santos, Jorge Isaac5, Núñez Martínez, Francisco Javier6, Flores, Homero Garcés7, Arballo Rivera, Gustavo Adolfo8, Flores Razo, Miriam Monzerrat9, Lizarazo Guiza, Paula Catalina10 catalina.lizarazo@astrazeneca.com |
| Source: |
Revista Alergia de Mexico. ene-mar2026, Vol. 73 Issue 1, p17-25. 9p. |
| Subjects: |
TREATMENT effectiveness, ANTIASTHMATIC agents, MEXICANS, ASTHMA, QUALITY of life |
| Geographic Terms: |
MEXICO |
| Abstract (English): |
OBJECTIVE: To evaluate the type and intensity of response to benralizumab and identify responders and super-responders amongst patients with severe uncontrolled eosinophilic asthma managed in Mexico. METHODS: A multicenter study in 3 hospitals in Mexico evaluating the Asthma Control Test and Asthma Control Questionnaire (ACT) scores; mini Asthma Quality of Life Questionnaire; peripheral blood eosinophils; exhaled fraction of nitric oxide; forced expiratory volume in 1 second before and after benralizumab treatment and the number of exacerbations at 12 months. RESULTS: The record of 28 patients with severe uncontrolled eosinophilic asthma were included. At 12-months, 82.1% were considered in asthma control, where 82% were responders and 64% classified as super-responders. 75% of patients had no exacerbations, with ACT scores improvement in 89% and 79% of patients discontinued maintenance corticosteroids. A total of 82% presented forced expiratory volume in 1 second values over 500 ml. ACT scores showed an average decrease of 1.35 points and a statistically significant decrease in serum eosinophils was observed. CONCLUSION: This is the first study in Mexico to evaluate the subgroup of super-responders to benralizumab who had clinical, laboratory and quality of life improvements. Besides the vast majority were responders and 64% super-responders at 12-months of treatment. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): |
OBJETIVO: Evaluar el tipo e intensidad de respuesta a benralizumab, e identificar a los pacientes respondedores y superrespondedores con asma eosinofílica grave. MÉTODOS: Estudio multicéntrico llevado a cabo en tres hospitales de México. Se evaluaron pacientes a través del Cuestionario de Control del Asma, mini cuestionario sobre calidad de vida en asma; además de la determinación de eosinófilos en sangre periférica, fracción exhalada de óxido nítrico, volumen de expiración forzada en 1 segundo (VEF1), antes y después de recibir tratamiento con benralizumab, y cantidad de exacerbaciones en 12 meses. RESULTADOS: Se analizaron los expedientes de 28 pacientes con asma eosinofílica grave, mal controlada. A los 12 meses, un 82.1% de los casos se clasificó en control, donde 82% fueron respondedores y 64% superrespondedores. El 75% de los pacientes no tuvo exacerbaciones, 89% mejoraron el puntaje ACT y 79% descontinuaron el tratamiento con corticoesteroides. Un 82% mostró un VEF1 mayor de 500 mL. Los puntajes de ACT demostraron una reducción promedio de 1.35 puntos y se reportó una reducción estadísticamente significativa de eosinófilos en sangre. CONCLUSIÓN: Este es el primer estudio en México que evalúa al subgrupo de pacientes superrespondedores a benralizumab con mejoría clínica, de laboratorio y calidad de vida. La mayoría fueron respondedores y 64% superrespondedores a los 12 meses de tratamiento [ABSTRACT FROM AUTHOR] |
|
Copyright of Revista Alergia de Mexico is the property of Coleg. Mexicano de Inmunologia Clinica y Alergia A.C.; Soc. Lat. de Alergia, Asma e Inmunologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
MedicLatina |
